Aspirin in polycythemia vera and essential thrombocythemia: Current facts and perspectives

Leukemia and Lymphoma

Volumn 22, Issue SUPPL. 1, 1996, Pages 83-86

  Landolfi, Raffaele ^a,c   Patrono, Carlo ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

Author keywords

Aspirin; Essential thrombocythemia; Polycythemia vera

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; THROMBOCYTE ENZYME; THROMBOXANE A2;

CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HUMAN; ICOSANOID METABOLISM; POLYCYTHEMIA VERA; PRIORITY JOURNAL; SHORT SURVEY; THROMBOCYTHEMIA; THROMBOSIS;

EID: 0029962594     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199609074365     Document Type: Short Survey

References (22)

1. Cortelazzo, S. Finazzi G., Ruggeri M., Vestri O., Galli M., Rodeghiero F. and Barbui, T. (1995) Hydroxyurea for patients with Essential Thrombocythemia and high risk of thrombosis. N. Engl. J. Med., 332, 1132-1136.
2. Najean, Y., Dresch, C. and Rain, J. D. (1994) The very-long-term course of polycythaemia - A complement to the previously published date of the polycythemia vera study group. Br. J. Haematol., 86, 233-235.
3. van den Anker-Lugtenburg, Sizoo, W. (1990) Myelodisplastic syndrome and secondary acute leukemia after treatment of essential thrombocythemia with hydroxyurea. Am. J. Hematol., 33, 152.
4. Kaplan, M. E., Mack, K., Goldberg, J. D., Donovan, P. B., Berk, P. D. and Wasserman, L. R. (1986) Long Term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol., 23, 167-71.
5. Antiplatelet Trialist's Collaboration. (1994) Collaborative overview of randomised trials of antiplatelet therapy - III: reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. BMJ, 308, 235-46.
6. Tartaglia, A., Goldber, J., Berk, P. and Wasserman, L. (1986) Adverse effects of antiaggregating platelet therapy in the treatment of polycythemia vera. Semin. Hematol., 23, 172-176.
7. Grosi, A., Rossetti, S., Vannucchi, A., Rafanelli, D. and Rossi Ferrini, P. (1988) Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders: a retrospective study of 108 patients. Clin. Lab. Haemat., 10, 167-175.
8. Gilbert, H. S. and Hanna, M. M. (1986) Low-dose aspirin/low hematocrit regimen: a safe and efficacious treatment for polycythemia vera. Blood, 68, 770a.
9. Frohli, P., Graf, C. and Rhyner, K. (1983) Die Prophylaxe vaskularer komplikationen bei polycythaemia vera und primarer thrombozythamie mit niedrig dosierter acetylsalicylsaure. Schweiz med Wschr., 113, 1622-1627.
10. Michiels, J., Abels, J., Steketee, J., van Vliet, H. H. D. M. and Vuzevski, K. D. (1985) Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia. Ann. Intern. Med., 102. 466-471.
11. van Genderen, P. J. J., Michiels, J. van Strik R., Lindemans, J. and van Vliet H. H. D. M (1995) Platelet consumption in thrombocythemia complicated by erythromelalgia: reversal by aspirin. Thromb. Haemostas., 73, 210-214.
12. Michiels, J., Koudstaal, P., Mulder, A. and van Vliet, H. (1993) Transient neorologic and ocular manifestation in primary thrombocythemia. Neurology, 43, 1107-1110.
13. Landolfi, R., Ciabattoni, G., Patrignani, P. et al. (1992) Increased thromboxane biosynthesis in patients with polycythemia vera: evidence for aspirin-suppressible platelet activation in vivo. Blood, 80, 1965-1971.
14. Rocca, B., Ciabattoni, G., Tartaglione, R. et al. (1995) Increased thromboxane biosynthesis in essential thrombocythemia. Thromb. Haemostas., in press.
15. Patrono, C. (1994) Aspirin as an antiplatelet drug. N. Engl. J. Med., 330, 1287-1294.
16. Patrignani, P., Filabozzi, P. and Patrono, C. (1982) Selective cumulative inhibition of platelet thromboxane productionby low-dose aspirin in healthy subjects. J. Clin. Invest., 69, 1366-72.
17. Patrono, C., Ciabattoni, G., Patrignani, P. et al. (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation, 72, 1177-84.
18. FitzGerald, G. A., Oates, J. A., Hawiger, J. et al. (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J. Clin. Invest., 71, 676-88.
19. De Caterina, R., Giannessi, D., Boem, A. et al. (1985) Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. Throm. Haemost., 54, 528-32.
20. Schafer, A. I. (1984) Bleeding and thrombosis in the myeloproliferative disorders. Blood, 64, 1-12.
21. van Genderen, P. and Michiels, J. (1994) Erythromelalgic, thrombotic and haemorrhagic manifestations of thrombocythaemia. Press Med., 23, 73-77.
22. Snethlage, W. and Ten Cate, J. (1986) Thrombocythaemia and recurrent late abortions. Normal outcome of pregnancies after anti-